glp 1 mast cell A newly published case series reports that GLP-1 receptor agonists (like semaglutide and tirzepatide) may significantly improve symptoms in patients with activation syndrome (MCAS), even in those without diabetes or Mast Cell Activation Syndrome (MCAS)

Peptide degradation can be visible (cloudiness, particulate matter, color change from clear to yellow or brown) or invisible (deamidation, oxidation, peptide bond hydrolysis detectable only by re-assay)

On the other hand, chronic alcohol abuse in combination with malnutrition (low hepatic GSH levels), longer duration of supratherapeutic APAP consumption, and older age with potential co-morbidities can trigger hepatotoxicity [179]

Neroni B, Evangelisti M, Radocchia G, et al

10.1016/j.cbpa.2010.12.001 Curr

And alcohol impairs judgment around food choices, which undermines the appetite management benefits the medication provides